1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Quality of life Assessment introduction
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
H EALTH R ELATED Q UALITY OF L IFE Fowad Khurshid PHCL
Rescuing Clinical Trial Data For Economic Evaluation
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
1 The Patient Perspective: Satisfaction Survey Presented at: Disease Management Colloquium June 22, 2005 Shulamit Bernard, RN, PhD.
1 Patient values or values from the general public.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
CIA Annual Meeting Session 3203 Measuring Wellness: The Issues? Tom Brogan President June 28 th, 2005.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Governance and Public Policy: a NICE example John Brazier Professor of Health Economics, ScHARR, University of Sheffield, UK With thanks to Matt Stevenson.
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Introduction to decision analysis Jouni Tuomisto THL.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Introduction to decision analysis Jouni Tuomisto THL.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Scaling Session Measurement implies assigning numbers to objects or events. In our case, the numbers “weight” responses to questions, so that saying “Yes”
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Global burden of diseases
Quality of Life Assessment
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
PUBLIC HEALTH – INTRODUCTION HEALTH STATUS OF A POPULATION
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy  Viersprong Institute for studies on Personality Disorders  Presentations can be found at: 

2 New cancer therapy SymptomsDrug XDrug Y Survival days Days sick of chemotherapy Days sick of disease TWiST

3 Time Without Symptoms of disease and subjective Toxic effects of treatment  TWiST  Developed by Richard Gelber (statistician)  In search for a typical “cancer” problem  Often prolonged life but also a reductions in quality of life At the beginning (side effects) At the end  Only count the days without symptoms of disease and subjective toxic effects of the treatment

4 TWiST in cancer therapy

5 Fit new therapy in fixed budget  50 patients each year (per hospital)  Drug x: 50 x euro = euro  Drug y: 50 x euro = euro  Drug budget for x or y = euro  Number of patient Drug x: euro / = 28.5 patients Drug y: euro / = 25.0 patients  Survival in days Drug x: 28.5 patients x 300 days = days Drug y: 25.0 patients x 400 days = days  Survival in TWiST Drug x: 28.5 patients x 190 TWiST = days Drug y: 25.0 patients x 220 TWiST = days

6 TWiST: ignores differences in quality of life  TWiST  Healthy = 1  Sick (dead) = 0  There is more to life than sick/health  Make intermediate values  Q-TWiST Quality of life adjusted adjusted TWiST  How to scale quality of life? 0.0 Quality of life 1.0

Quality of life  “…. Health is physical, mental and social well- being and not merely the absence of disease or infirmity...”  World Health Organization, 1947  Extending health to well-being: Quality of life  What is the definition of quality of life?

Definitions of Quality of Life  Quality of life is the degree of need and satisfaction within the physical, psychological, social, activity, material and structural area (Hörnquist, 1982).  Quality of life is the subjective evaluation of good and satisfactory character of life as a whole (De Haes, 1988).  Health related quality of life is the subjective experiences or preferences expressed by an individual, or members of a particular group of persons, in relation to specified aspects of health status that are meaningful, in definable ways, for that individual or group (Till, 1992).  Quality of life is a state of well-being which is a composite of two components: 1) the ability to perform everyday activities which reflects physical psychological, and social well-being and 2) patient satisfaction with levels of functioning and the control of disease and/or treatment related symptoms (Gotay et al., 1992).  An individual’s perception of their position in life in the context of the culture and values systems in which they live and in relation to their goals, expectations, standards and concerns (WHO Quality of life Groups, 1993).

No clear definition because:…  Many possible definitions  Researchers are free to choose  The notion of measuring the quality of life could include the measurement of practically anything of interest to anybody. And, no doubt, everybody could find arguments supporting the selection of whichever set of indicators to be his choice (Andrews & Withy, 1976, page 6)  Different origins of research  Clinical decision making:… does the patient benefit from the treatment?  Epidemiology (public health):… what is the morbidity of the population?  Health economics:… is it worth the money?

Common items in definitions:  It is not the doctor who reports  Quality of life is subjective….  “Given its inherently subjective nature, consensus was quickly reached that quality of life ratings should, whenever possible, be elicited directly from patients themselves. “ (Aaronson, in B Spilker (Ed): Quality of life and Pharmacoeconomics in Clinical Trails, 1996, page 180)

Common items in definitions:  Health related  Multidimensional  Physical, psychological, social  Questionnaires  Standardize questions and response Reproducible results: sciences Quantify subjectivity  Operational defined  Like IQ and temperature.

How to measure quality of life form a clinical point of view?  Choose items  Are you able to walk one kilometer ?  Do you feel depressed ?  Choose response mode  Binary yes / no  Multiple (Likert) yes / at bid / hardly / no  Continuous ( Visual Analogue Scale ) Always ————X—— Never  Combine items to dimensions of quality of life  Sum up the items belonging to one dimension  Rescale sum on a scale from 0 to 100

13 SF-36

14 SF-36

15 Multidimensionality in outcomes in health care  What if outcome conflict…  e.g: better mobility, but worse roll emotional  On has to weight or combine outcomes  What if some patients dies?  Cancer therapy Better quality of life, but higher mortality  Weight quality of life with mortality

16 Value a health state  Wheelchair  Some problems in walking about  Some problems washing or dressing  Some problems with performing usual activities  Some pain or discomfort  No psychosocial problems

17 Visual Analogue Scale  VAS  Also called “category scaling”  From psychological research  “How is your quality of life?”  “X” marks the spot  Rescale to [0..1]  Different anchor point possible:  Normal health (1.0) versus dead (0.0)  Best imaginable health versus worse imaginable health Dead Normal health X

18 EuroQol EQ-5D  MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed  SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself  USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities  PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort  ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

19 Ratio scale in QoL  If we want to weight dimensions of QoL….  Values should be (at least) on interval scale  Is it possible?  My Qol is today twice as good as yesterday  Her IQ is twice as high…  This painting is twice as beautiful as…  His depression is twice as…  My lecture is twice as….  Is a VAS ratio or interval?

20 Uni-dimensional value  Ratio or interval scale  Difference 0.00 and 0.80 must be 8 time higher than 0.10  Two methods have these pretensions  Time trade-off  Standard gamble

21 Time Trade-Off  TTO  Wheelchair  With a life expectancy: 50 years  How many years would you trade-off for a cure?  Max. trade-off is 10 years  QALY(wheel) = QALY(healthy)  Y * V(wheel) = Y * V(healthy)  50 V(wheel) = 40 * 1  V(wheel) =.8

22 Standard Gamble  SG  Wheelchair  Life expectancy is not important here  How much are risk on death are you prepared to take for a cure?  Max. risk is 20%  wheels = (100%-20%) life on feet  V(Wheels) = 80% or.8

23 TWiST: ignores differences in quality of life  TWiST  Healthy = 1  Sick (dead) = 0  There is more to life than sick/health  Make intermediate values  Q-TWiST Quality of life adjusted adjusted TWiST  How to scale quality of life? 0.0 Quality of life 1.0

24 In health economics: Q-TWiST = QALY  Count life years  Value (V) quality of life (Q)  V(Q) = [0..1] 1 = Healthy 0 = Dead  One dimension  Adjusted life years (Y) for value quality of life  QALY = Y * V(Q) Y: numbers of life years Q: health state V(Q): the value of health state Q  Also called “utility analysis”

25  A new wheelchair for elderly (iBOT)  Special post natal care Which health care program is the most cost-effective?

26  A new wheelchair for elderly (iBOT)  Increases quality of life = 0.1  10 years benefit  Extra costs: $ 3,000 per life year  QALY = Y x V(Q) = 10 x 0.1 = 1 QALY  Costs are 10 x $3,000 = $30,000  Cost/QALY = 30,000/QALY  Special post natal care  Quality of life = 0.8  35 year  Costs are $250,000  QALY = 35 x 0.8 = 28 QALY  Cost/QALY = 8,929/QALY Which health care program is the most cost-effective?

27 QALY league table

ABC Utility of Health Egalitarian Concerns: Burden of disease

29 Implications shifting threshold  QALY are weighted  Weighted QALYs are maximized  Health is no longer the only thing maximized  Health status population will drop  Differences in health will drop  Egalitarian consideration are incorporated  Burden of disease becomes a criteria  Equity

30 CE-ratio by equity

31 Conclusion  Cost effectiveness in medicine can be measured  Burden of disease is also a criterion

32 The YAVIS patient in psychology  YAVIS  Young, Attractive, Verbal, Intelligent and Successful Young, Attractive, Verbal, Intelligent, and Successful Young, Attractive, Verbal, Insightful, and Successful Young, Attractive, Vital, Intelligent, and Successful Young, Affluent, Verbal, Insured, and Single  Is there a ‘need’ for treatment?  Is the QoL low?

33 Personality disorder is not YAVIS

34 Patient values or values from the general public

35 The clinical perspective  Quality of life is subjective…..  “Given its inherently subjective nature, consensus was quickly reached that quality of life ratings should, whenever possible, be elicited directly from patients themselves. “ (Aaronson, in B Spilker (Ed): Quality of life and Pharmacoeconomics in Clinical Trails, 1996, page 180)  The patient values count in clinical quality of life research

36 Coping (response shift)  Stensman  Scan J Rehab Med 1985;17:  Scores on a visual analogue scale  36 subjects in a wheelchair  36 normal matched controls  Mean score  Wheelchair: 8.0  Health controls: 8.3 Healthy Death

37 The economic perspective  In a normal market: the consumer values count  The patient seems to be the consumer  Thus the values of the patients….  If indeed health care is a normal market…  But is it….?

38 Health care is not a normal market  Supply induced demands  Government control  Financial support (egalitarian structure)  Patient  Consumer  The patient does not pay  Consumer = General public  Potential patients are paying  Health care is an insurance market  A compulsory insurance market

39 Health care is an insurance market  Values of benefit in health care have to be judged from a insurance perspective  Who values should be used the insurance perspective?

40 Who determines the payments of unemployment insurance?  Civil servant  Knowledge: professional  But suspected for strategical answers more money, less problems identify with unemployed persons  The unemployed persons themselves  Knowledge: specific  But suspected for strategical answers  General public (politicians)  Knowledge: experience  Payers

41 Who’s values (of quality of life) should count in the health insurance?  Doctors  Knowledge: professional  But suspected for strategical answers See only selection of patient Identification with own patient  Patients  Knowledge: disease specific  But suspected for strategical answers  But coping  General public  Knowledge: experience  Payers  Like costs: the societal perspective

42 The general public should be informed…  Valuing without knowledge makes no sense  Thyroid Eye Disease  Give description of the disease A patient with bilateral thyroid eye disease with upper lid retraction and exophthalmos.

43 …or use validated questionnaires MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

44 Validated Questionnaires in the societal perspective  Describe health states  Have values from the general public  Rosser Matrix  QWB  15D  HUI Mark 2  HUI Mark 3  EuroQol EQ-5D

45 Different perspective belong to different research questions  Health economics  Societal perspective General public  Medical decision making  Patients perspective  Epidemiology  Doctors perspective Global Burden of Disease